Sascha A. Tuchman, MD, MHS
Dr. Tuchman is an expert in managing patients with multiple myeloma, amyloidosis, and other plasma cell disorders. His clinical research focuses on treating multiple myeloma in patients who are at high risk for toxicity due to advanced age or other medical problems; developing novel drugs for treating all patients with multiple myeloma; and optimizing management for amyloidosis. He is a member of international working groups that formulate guidelines for treating these disorders.
Samuel Rubinstein, MD, MSCI
Dr. Rubinstein is both a hematologist and medical oncologist, as well as a clinical researcher. His primary areas of clinical and research interest are plasma cell disorders such as multiple myeloma and light chain (AL) amyloidosis. He has interests in improving our ability to predict outcomes and responses to therapy, as well as in conducting clinical trials both of therapeutics and novel supportive care approaches for patients with plasma cell disorders. He also works on ways to leverage the electronic health record to answer important clinical questions in the area of plasma cell disorders and is involved in various efforts to understand the outcomes of patients with cancer and COVID-19.
